Premium Nahrungsergänzungsmittel | artgerecht

Lipopolysaccharide (LPS) – Endotoxin & Immune Response

Lipopolysaccharide (LPS) is a key component of the outer membrane of gram-negative bacteria and is a potent activator of the human immune system, playing a central role in infections and inflammatory responses.

Regular tips about health Regular tips about health

Things worth knowing about "Lipopolysaccharide"

Lipopolysaccharide (LPS) is a key component of the outer membrane of gram-negative bacteria and is a potent activator of the human immune system, playing a central role in infections and inflammatory responses.

What is Lipopolysaccharide?

Lipopolysaccharide (LPS), commonly referred to as an endotoxin, is a complex molecule found in the outer membrane of gram-negative bacteria. It is composed of a lipid component (Lipid A), a core polysaccharide, and a variable O-antigen chain. LPS is released when bacteria die or divide and acts as a powerful trigger of the human immune response.

Structure of Lipopolysaccharide

LPS consists of three main structural components:

Lipid A: The fatty acid-containing anchor embedded in the bacterial membrane. It is the biologically active portion responsible for the toxic properties of LPS and the induction of immune responses.
Core polysaccharide: A sugar chain linking Lipid A to the outer O-antigen. It is relatively conserved among related bacterial species.
O-antigen: A highly variable polysaccharide chain that differs between bacterial strains and is used for serotyping and bacterial identification.

Mechanism of Action and Immune Response

When LPS enters the human body, it is recognized as a danger signal by the immune system. The blood protein LPS-binding protein (LBP) captures LPS and presents it to the CD14 receptor on immune cells. This subsequently activates Toll-like receptor 4 (TLR4), triggering a cascade of inflammatory reactions including:

Release of pro-inflammatory cytokines such as TNF-alpha, interleukin-1 (IL-1), and interleukin-6 (IL-6)
Activation of macrophages and neutrophils
Induction of fever
Vasodilation and increased vascular permeability

In small amounts, this immune response is beneficial for fighting infections. However, when large amounts of LPS are released simultaneously, the response can become dangerously excessive.

Clinical Significance

Sepsis and Septic Shock

One of the most severe consequences of massive LPS release is sepsis (blood poisoning) and, in critical cases, septic shock. This involves an uncontrolled, systemic inflammatory response that can lead to multi-organ failure and death. LPS from gram-negative bacteria is considered a primary trigger of these life-threatening conditions.

Chronic Inflammation

Even chronically elevated, low-grade LPS levels in the bloodstream -- a condition known as metabolic endotoxemia -- have been linked to a range of chronic diseases, including:

Type 2 diabetes
Obesity
Cardiovascular diseases
Chronic inflammatory bowel diseases

Gut Microbiome and LPS

The gut is a major source of LPS, as it harbors a large population of gram-negative bacteria. A compromised intestinal barrier (often referred to as leaky gut) can allow LPS to enter the bloodstream and promote systemic inflammation. A balanced diet and a healthy gut microbiome may help reduce intestinal LPS translocation.

Diagnostic Relevance

The Limulus Amebocyte Lysate (LAL) test is the gold standard for measuring LPS concentrations in pharmaceutical products, water, and blood samples. The test is based on a clotting reaction derived from the blood of the horseshoe crab, which is highly sensitive to LPS. In clinical settings, LPS measurement can support the diagnosis of gram-negative infections and help assess sepsis risk.

Therapeutic Approaches

Neutralizing or blocking LPS activity is an active area of medical research. Current and investigational therapeutic strategies include:

Antibiotics: Eliminating gram-negative bacteria to prevent further LPS release
LPS neutralizers: Substances such as polymyxin B that directly bind and neutralize LPS
TLR4 antagonists: Compounds that block the LPS receptor and dampen the inflammatory response
Dietary interventions: Dietary fiber and omega-3 fatty acids may help reduce intestinal LPS translocation and systemic inflammation

References

Rietschel, E. T. et al. - Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB Journal, 1994.
Cani, P. D. et al. - Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 2007.
World Health Organization (WHO) - Sepsis Fact Sheet. Available at: https://www.who.int/news-room/fact-sheets/detail/sepsis

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.